IPSEY News Alert Ipsen S.A. ADR (IPSEY) 12.9800 12/26/2014 0

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Ipsen S.A. ADR (IPSEY) 12.9800 $IPSEY

FDA clears expanded label for Ipsen's Somatuline Depot
Seeking Alpha - at Seeking Alpha - Wed Dec 17, 6:56AM CST


Ipsen's Somatuline(R) Depot(R) is the First Therapy Approved by the FDA in the United States for the Treatment of Patients with Locally Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumors
Business Wire - Tue Dec 16, 4:00PM CST
--US organization ready for launch in Q1 2015

Ipsen Announces the FDA Approval of Somatuline(R) Depot(R) (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors
Business Wire - Tue Dec 16, 3:45PM CST
Ipsen Biopharmaceuticals, Inc., an affiliate of Ipsen (Euronext: IPN; ADR: IPSEY), today announced that Somatuline(R) Depot(R) (lanreotide) Injection 120 mg (referred to as Somatuline(R)) was approved by the U.S. Food and Drug Administration (FDA) for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adult patients with unresectable, well or moderately differentiated, locally advanced or metastatic disease to improve progression-free survival (PFS).

Francois Garnier Appointed Executive Vice President, General Counsel of Ipsen
Business Wire - Tue Dec 16, 11:00AM CST
Regulatory News:

FDA clears expanded label for Novartis' Signifor
Seeking Alpha - at Seeking Alpha - Tue Dec 16, 6:10AM CST

NVS: 93.91 (+0.66)

Ipsen Announces That the International Breast Cancer Study Group (IBCSG) Presented Phase 3 Results Evaluating the Use of Ovarian Suppression to Adjuvant Treatment with Tamoxifen
Business Wire - Fri Dec 12, 12:00AM CST
--Ovarian suppression was obtained entirely by monthly injections of triptorelin over 5 years for 81% of patients

Ipsen Biopharmaceuticals, Inc. Announces FDA Acceptance of Filing for Dysport(R) (abobotulinumtoxinA) in the Treatment of Upper Limb Spasticity in Adult Patients
Business Wire - Mon Dec 01, 9:31AM CST
Ipsen Biopharmaceuticals, Inc., an affiliate of Ipsen (Euronext:IPN; ADR:IPSEY), today announced that the U.S. Food and Drug Administration (FDA) has accepted for review its supplemental Biologics License Application (sBLA) for Dysport(R) (abobotulinumtoxinA) for the treatment of upper limb spasticity in adult patients.

FDA agrees to review Ipsen Dysport label expansion application
Seeking Alpha - at Seeking Alpha - Fri Nov 28, 7:30AM CST


Ipsen Announces FDA Acceptance of Filing for Dysport(R) in the Treatment of Upper Limb Spasticity in Adult Patients
Business Wire - Fri Nov 28, 12:00AM CST
Regulatory News:

Ipsen Biopharmaceuticals, Inc. Announces IPSEN CARES(TM), An Enhanced Patient Support Program
Business Wire - Mon Nov 24, 9:42AM CST
Ipsen Biopharmaceuticals, Inc., an affiliate of Ipsen (Euronext: IPN; ADR: IPSEY) today announced the implementation of IPSEN CARES(TM) (Coverage, Access, Reimbursement, & Education Support). Ensuring patients, providers and caregivers have the resources needed to help access the Ipsen medications that are critical to managing their conditions, IPSEN CARES is staffed Monday to Friday by experts who can assist with a broad range of medical, educational, logistical and coverage information regarding Ipsen medicines, including Increlex(R) (mecasermin), Somatuline(R) Depot(R) (lanreotide), and Dysport(R) (abobotulinumtoxinA).

Lexicon Pharmaceuticals Fights On
Stephen Simpson, CFA - at Seeking Alpha - Fri Nov 21, 11:09AM CST

LXRX: 0.90 (+0.02)

Ipsen and CNRS Create the "Archi-Pex" Joint Research and Innovation Lab, in Collaboration with the University of Rennes 1 and CEA
Business Wire - Thu Nov 20, 11:00AM CST
--Five-year public-private research partnership, built on 15 years of collaboration

Ipsen and the Salk Institute renew their agreement for discovery research in medical sciences
Business Wire - Tue Nov 18, 12:00AM CST
--Ipsen to support innovative Salk investigations into biology for another three years

Ipsen Announces FDA Approval of a New Delivery Device for Somatuline(R) Depot(R) (lanreotide) Injection
Business Wire - Thu Nov 06, 9:06AM CST
Ipsen Biopharmaceuticals, Inc., an affiliate of Ipsen (Euronext: IPN; ADR: IPSEY), today announced that the U.S. Food and Drug Administration (FDA) has approved a new device to deliver Somatuline(R) Depot(R) (lanreotide). The device has an enhanced, prefilled, low-volume syringe that supports full-dose delivery with no reconstitution requirements.

Otonomy Obtains Rights to Gacyclidine Data From Ipsen to Support Development of OTO-311 as a Treatment for Tinnitus
GlobeNewswire - Thu Nov 06, 12:00AM CST
Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the inner and middle ear, and Ipsen (Euronext:IPN) (ADR:IPSEY), a global specialty-driven pharmaceutical company, today announced that they have entered into an exclusive licensing agreement enabling Otonomy to utilize Ipsen's gacyclidine data in the development and registration of OTO-311. OTO-311 is Otonomy's sustained-exposure formulation of gacyclidine, an N-Methyl-D-Aspartate (NMDA) receptor antagonist, in development for the treatment of tinnitus.
OTIC: 32.26 (+0.65), IPN: 29.31 (+0.24)

Otonomy obtains rights to gacyclidine data from Ipsen to support development of OTO-311 as a treatment for tinnitus
Business Wire - Thu Nov 06, 12:00AM CST
Regulatory News:
OTIC: 32.26 (+0.65)

Ipsen Biopharmaceuticals, Inc. Announces Hire of Donald Pearl as Vice President of Neurology
Business Wire - Wed Nov 05, 8:37AM CST
Ipsen Biopharmaceuticals, Inc., an affiliate of Ipsen (Euronext: IPN; ADR: IPSEY), today announced that Donald Pearl has joined the company as Vice President of Neurology. Mr. Pearl will work closely with senior leadership to build out the neurology commercial structure in the U.S. as Ipsen builds upon its 20 years of clinical experience with Dysport(R) (abobotulinumtoxinA) and pursues a comprehensive and ambitious neurotoxin clinical study program.
AGN: 210.12 (+0.95)

Ipsen: sales in the 3rd quarter and first nine months of 2014
Business Wire - Wed Oct 29, 1:00AM CDT
--Dysport(R) up 18.9%(1), helped by exceptional orders from Group partner in aesthetic medicine

Lexicon and Ipsen enter into ex-North America/Japan licensing and commercialization agreement for telotristat etiprate
Business Wire - Wed Oct 22, 12:07AM CDT
--Lexicon to potentially receive $145 million in upfront and milestone payments, plus royalties
LXRX: 0.90 (+0.02)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

CVS Puts Youth Soccer Stories on Its Store Shelves

Updated Category News Views 60

Two kids with real community ties just got a megaphone most grown-ups never receive. CVS Pharmacy has named Caroline, 9, of Holmes Beach, Florida, and Zoe, 12, of Los Angeles, as the first grand-prize winners of its Home Team Heroes youth soccer contest. Each player’s selected nonprofit soccer organization will receive a $25,000 grant, while their stories will appear on...

Continue Reading
Art Limitless Jury Puts SDG 12 and Art Into Clear Focus

Updated Category News Views 56

A paint pigment, a discarded object, and a serious climate question have landed in the same room. BE OPEN Art’s 2026 Art Limitless competition is aimed at SDG 12, the United Nations goal centered on responsible production and consumption. That may sound like institutional language built for conference folders, but the underlying issue is plain enough: society cannot...

Continue Reading
Tessera Delisting Leaves HLSQ in a Tougher Market Ahead

Updated Category News Views 0

November delivered a nasty little truth serum for Tessera Defense and Homeland Security: exchange status is not a cosmetic detail when the stock’s selling price has collapsed. On November 10, NYSE Regulation suspended trading in the company’s common shares on NYSE American and began delisting proceedings. By November 17, Tessera had a chance to request review by the...

Continue Reading
PPL's January Dividend Keeps Utility Appeal Intact

Updated Category News Views 85

A dividend notice is rarely thrilling, but it can still separate a steady utility from a story stock peddling fumes. PPL Corporation declared a quarterly common dividend of $0.2850 per share on Nov. 20, payable Jan. 4, 2027. Shareholders must be on the books by Dec. 10, 2026, to receive it. Plain vanilla stuff, yes. Still, plain vanilla is often precisely why utility...

Continue Reading
Swim Readiness Depends on Skills, Not Birthdays Alone

Updated Category News Views 34

A child popping up calmly after a brief dunk tells you more than a birthday ever will. That is the sensible center of Woody Alpern's guidance for families weighing whether a child belongs in the next swim level. The Atlanta swim school expert's point is refreshingly free of the usual parental race: advancement is earned through repeatable skills, comfort, and judgment in...

Continue Reading
Classic Chevrolet Gives $1.145M to 13 Local Groups

Updated Category News Views 16

A Thanksgiving Check With Some Real Weight More than a million dollars changing hands before lunch is not the usual holiday fluff, and Classic Chevrolet's planned $1,145,040 donation deserves more than a quick nod. On Tuesday, November 24, at 11 a.m. CST, the Grapevine dealership says it will distribute that sum among 13 nonprofit organizations and charitable programs...

Continue Reading
CCTV-4 Revisits China's Enduring Academy Tradition

Updated Category News Views 76

Stone courtyards, old books and hard questions are getting prime time on CCTV-4, which is a more interesting programming bet than it may first appear. Enduring Chinese Academies, a ten-episode cultural exploration series from China Media Group's Global Chinese Programming Center, is built around a simple theme: “One academy, one spirit.” It begins airing November 22...

Continue Reading
Lara Kirchner's Surgical Leadership Earns Recognition

Updated Category News Views 33

Surgical care gets judged in the quiet moments nobody puts on a plaque: a sterile instrument ready when it must be, a handoff done cleanly, a team that does not let a rushed schedule turn into a bad outcome. That is why Lara L. Kirchner's recognition as a Pinnacle Professional of the Year deserves a more serious look than the usual congratulatory confetti. Kirchner is...

Continue Reading
New York Gala Puts $3 Million Behind EB Research Work

Updated Category News Views 54

Three million dollars changes the temperature in a research room, even if it does not magically solve the hard part. EB Research Partnership said its New York gala raised more than $3 million, with Eddie Vedder, Hozier, Tom Holland and Colin Farrell among the names helping draw attention. For a nonprofit operating around research, that is not a fluffy society-page...

Continue Reading
Faex Health Adds Ebola and H. pylori AI Screening Tools

Updated Category News Views 15

A smartphone pointed at a toilet is an awkward place to hunt for medical progress, yet Faex Health is making a serious attempt to turn that daily evidence into an early-warning tool. The company has added investigational pre-screening capabilities for Ebola virus disease and Helicobacter pylori, or H. pylori, bringing its internally validated panel to 18 gastrointestinal...

Continue Reading

Top 5 Most Recently Viewed Articles

Investors Alert: Join Class Action Against Vestis Corporation

Updated Category News Views 240

Important Notice for Investors in Vestis Corporation Levi & Korsinsky, LLP is reaching out to those who have invested in Vestis Corporation (NYSE: VSTS) regarding a significant class action securities lawsuit. This initiative is intended for individuals who believe they faced losses as a consequence of the alleged securities fraud involving the company. Understanding the...

Continue Reading
Wegovy's Impact on MASH Care: Insights into Physician Adoption

Updated Category News Views 168

Wegovy's Revolutionary Role in MASH Treatment Wegovy, known in the medical community as semaglutide 2.4mg, has recently garnered approval as a treatment for metabolic dysfunction-associated steatohepatitis (MASH). This development is viewed as a crucial advancement for a condition that affects a substantial patient population. With significant unmet needs, the...

Continue Reading
Opportunity for Orthofix Investors to Join Class Action Lawsuit

Updated Category News Views 248

Class Action Lawsuit Opportunity for Orthofix Investors Investors in Orthofix Medical Inc. have been alerted to a significant opportunity. A class action lawsuit is underway against Orthofix, involving allegations against current and former officers for violations of federal securities laws. If you are among those who encountered substantial losses due to the handling of...

Continue Reading
Meta Strengthens AI Infrastructure with Rivos Acquisition

Updated Category News Views 252

Meta Platforms Aims for AI Dominance Meta Platforms (NASDAQ:META) is making significant strides in the realm of artificial intelligence, channeling resources into massive chip investments and potential acquisitions to bolster its infrastructure. As one of the giants in U.S. technology, Meta is set on further establishing its presence in AI technology with a commitment of...

Continue Reading
Renovating Older Homes? Structural Insight is Key

Updated Category News Views 28

Unearthing the Bones of Older Homes It ain't rocket science to realize that before you swing a sledgehammer in an old house, you’d better know what you’re dealing with. The walls might look like just a bunch of paint and plaster, but underneath, they tell stories older than most of us. It's all laid out in this HelloNation chat with Jason Marks from Ward Construction....

Continue Reading